by Shannon Van Hoesen
Environmental Working Group

Excerpts:

The decision by an organization of the world’s leading cancer experts to classify the herbicide 2,4-D as a possible carcinogen underscores the risk posed by the U.S. government’s recent approval of 2,4-D for use on genetically engineered, or GMO, crops.

The International Agency for Research on Cancer (IARC), a branch of the World Health Organization, said 2,4-D is “possibly carcinogenic to humans” because there is “strong evidence that 2,4-D induces oxidative stress that can operate in humans and moderate evidence that 2,4-D causes immunosuppression, based on in-vivo and in-vitro studies.”

“We have known for decades that 2,4-D is harmful to the environment and human health, especially for the farmers and farm workers applying these chemicals to crops,” said Mary Ellen Kustin, senior policy analyst for the Environmental Working Group. “Now that farmers are planting 2,4-D-tolerant GMO crops, this herbicide is slated to explode in use much the way glyphosate did with the first generation of GMO crops. And we know from experience—and basic biology—that weeds will soon grow resistant to these herbicides, making GMO crop growers only more dependent on the next chemical fix.”

2,4-D is one of the two active ingredients in Enlist Duo, a toxic weed-killing cocktail marketed by Dow AgroSciences, which the U.S. Environmental Protection Agency recently approved for use in 15 states. The other herbicide in Enlist Duo is glyphosate, which the international cancer agency had previously classified as “probably carcinogenic.” Exposure to both chemicals has separately been linked to non-Hodgkin lymphoma.

Read the Full Article Here.

The Healthy Traditions Glyphosate-tested Program. Foods with this logo have been tested for the presence of glyphosate.

We Lost the War on Cancer – Review of Alternative Cancer Therapies

eBook
Retail : $9⁹⁹
Now : $5⁹⁹

We have lost the war on cancer. At the beginning of the last century, one person in twenty would get cancer. In the 1940s it was one out of every sixteen people. In the 1970s it was one person out of ten. Today one person out of three gets cancer in the course of their life.

The cancer industry is probably the most prosperous business in the United States. In 2014, there will be an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US. $6 billion of tax-payer funds are cycled through various federal agencies for cancer research, such as the National Cancer Institute (NCI). The NCI states that the medical costs of cancer care are $125 billion, with a projected 39 percent increase to $173 billion by 2020.

The simple fact is that the cancer industry employs too many people and produces too much income to allow a cure to be found. All of the current research on cancer drugs is based on the premise that the cancer market will grow, not shrink.

John Thomas explains to us why the current cancer industry prospers while treating cancer, but cannot afford to cure it in Part I. In Part II, he surveys the various alternative cancer therapies that have been proven effective, but that are not approved by the FDA.